AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 613552
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with prednisolone - initial dosage of 30 mg followed by reduced dosage for 6 months
Trial: 28822974
Drug: Dexmedetomidine (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (3.5 μg/kg + 5 μg/kg/hour CRI)
Trial: 28822974
Drug: Dexmedetomidine (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (3.5 μg/kg + 3.5 μg/kg/hour CRI) and Butorphanol (20 μg/kg + 24 μg/kg/hour CRI)
Trial: 24791752
Drug: Oral GSH
RxNorm normalized name: GSH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GSH 1,000 mg/day
Trial: 24791752
Drug: Oral GSH
RxNorm normalized name: GSH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GSH 250 mg/day
Trial: 23499546
Drug: Topical fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluorouracil (16 weeks, twice a week)
Trial: 23499546
Drug: Electrocautery (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrocautery (monthly for 4 months)
Trial: 23499546
Drug: Topical fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluorouracil
Trial: 18034397
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination therapy of dexamethasone and gentamicin
Trial: 17974421
Drug: 1‐alpha(OH) vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐alpha(OH) vitamin D3 (0.25 mcg twice a day)
Trial: 17974421
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with calcium (500 mg daily)
Trial: 27082747
Drug: Behavioral treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatments for substance use (specifics not provided)
Trial: 25087414
Drug: Intravenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous laser blood irradiation for 10 days, using a laser therapeutic device Matrix - VLOK with two radiating heads (KI-VLOK-63 and KI-VLOK-365).
Trial: 10084637
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day risperidone
Trial: 10084637
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day risperidone
Trial: 10084637
Drug: 0.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/day risperidone
Trial: 7474246
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol (0.5%) eye drops
Trial: 7474246
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol (0.5%) eye drops with oral quinidine (50 mg)
Trial: 2270452
Drug: Paracetamol (i.v.)
RxNorm normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (i.v.)
Trial: 25845393
Drug: Daily reminders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily reminders via alarm and follow-up calls from peer-educators
Trial: 19058060
Drug: Balance-strategy training
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance-strategy training program (twice-weekly for 12 weeks)
Trial: 15289275
Drug: Tryptophan depletion
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan depletion (TD) induced by administering capsules containing an amino acid mixture without tryptophan.
Trial: 15289275
Drug: Sham depletion
RxNorm normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham depletion using identical capsules containing hydrous lactose.
Trial: 22784432
Drug: Optimized rapeseed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized rapeseed oil (20 g/d)
Trial: 22784432
Drug: Standard rapeseed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rapeseed oil (20 g/d)
Trial: 16497603
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (NRT) using a nicotine skin patch for 2 weeks before the quit date, with doses of 0, 21, or 42 mg/24-hr after the quit date in combination with mecamylamine (10 mg/day).
Trial: 16497603
Drug: Nicotine skin
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine skin patch treatment
Trial: 16497603
Drug: Nicotine skin
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine skin patches with reduced-nicotine cigarettes
Trial: 11704711
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (exact dosage and duration not specified)
Trial: 9397385
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal norethisterone acetate (NETA) 170 micrograms
Trial: 9397385
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal norethisterone acetate (NETA) 350 micrograms
Trial: 9397385
Drug: Sequential oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential oral progestogen (1 mg norethisterone or 20 mg dydrogesterone/day)
Trial: 9397385
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal progestogen
Trial: 9397385
Drug: Continuous progestogen
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous progestogen (low-dose)
Trial: 9397385
Drug: Continuous progestogen
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous progestogen (high-dose)
Trial: 9397385
Drug: Oral progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral progestogen group
Trial: 20606148
Drug: Glucosamine (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine (1500 mg daily for 6 months)
Trial: 31910279
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 6 months)
Trial: 12887260
Drug: Interferon (IFN)‐beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN)‐beta treatment
Trial: 9773135
Drug: Droperidol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg
Trial: 26332408
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment with fixed appliances
Trial: 25945760
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without orthodontic treatment)
Trial: 7978092
Drug: Ethanol 0.5
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.5 g/kg
Trial: 11590628
Drug: Rank-based methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rank-based methods for analysis of outcomes with rescue medication
Trial: 11590628
Drug: Multilevel regression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multilevel regression model relating outcome to allocated treatment and rescue status
Trial: 8022438
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (20 mg intravaginally every 3 hours)
Trial: 24395021
Drug: Guanfacine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (2 or 3 mg)
Trial: 20694776
Drug: Chinese drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese drugs administered by both oral intake and retention enema (Group A)
Trial: 20694776
Drug: Chinese drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese drugs given by retention enema only (Group B)
Trial: 20694776
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Group C)
Trial: 19080647
Drug: Oxaliplatin plus
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (40-45 Gy, 5 times a week)
Trial: 19080647
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (Control Group II)
Trial: 19080647
Drug: Oxaliplatin plus
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (for resectable patients)
Trial: 19080647
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (Control Group II for resectable patients)
Trial: 19080647
Drug: Oxaliplatin plus
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (for un-resectable patients)
Trial: 19080647
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (Control Group II for un-resectable patients)
Trial: 18046028
Drug: Eltrombopag 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 30 mg daily
Trial: 23497336
Drug: Eltrombopag (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (any dose)
Trial: 8108576
Drug: Pamidronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (30 mg a day for 3 consecutive days)
Trial: 8108576
Drug: Clodronate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (300 mg a day for 3 consecutive days)
Trial: 31491758
Drug: Topical vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical vancomycin
Trial: 29224823
Drug: Cabazitaxel (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (20 mg/m2)
Trial: 19541917
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy (RT)
Trial: 19541917
Drug: Intensive comparison
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive comparison therapy (ICT)
Trial: 17503984
Drug: Paroxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (60 mg/day)
Trial: 15072661
Drug: Stepwise band-filling
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise band-filling during 6 monthly ambulant visits
Trial: 29738877
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TXA) 2 g orally 2 h preoperatively and two doses of 1 g TXA postoperatively
Trial: 29738877
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) 3 g administered in the operating room
Trial: 29544472
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TXA)
Trial: 29738877
Drug: Topical group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical group
Trial: 21246842
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of rHuEpo at Zusanli (ST 36) and Shenshu (BL 23), 3 times a week for 2 months.
Trial: 21246842
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of rHuEpo, 3 times a week for 2 months (Control group).
Trial: 10408542
Drug: High-dose transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose transdermal 17beta-estradiol (four skin patches each releasing 0.1 mg of estradiol daily, replaced every 2 to 3 days)
Trial: 7579128
Drug: Mepyramine (histamine‐H1‐receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepyramine (histamine‐H1‐receptor antagonist) pretreatment
Trial: 2123881
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate and human menopausal gonadotrophin (CC/HMG)
Trial: 26027245
Drug: Etoricoxib (ET)
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (ET) 90 mg continuously every day
Trial: 26027245
Drug: Etoricoxib (ET)
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (ET) 90 mg intermittently 1‐3 times weekly
Trial: 23345574
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of prophylactic antibiotics
Trial: 14871253
Drug: rFVIIa (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa (90 microg/kg i.v.) given 3 h after idraparinux (7.5 mg s.c.)
Trial: 14871253
Drug: rFVIIa (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa (90 microg/kg i.v.) given 1 week after idraparinux (7.5 mg s.c.)
Trial: 11528604
Drug: Multidisciplinary behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary behavioral treatment
Trial: 7702020
Drug: Fructose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (50 g) added to a standard (40-g oral) fat load
Trial: 2484836
Drug: Livingston's chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Livingston's chemotherapy combined with isoprinosine
Trial: 2484836
Drug: Livingston's chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Livingston's chemotherapy with shortened treatment cycle (8 days) and isoprinosine
Trial: 2484836
Drug: Livingston's chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Livingston's chemotherapy (control group)
Trial: 27101815
Drug: Fulranumab 6mg
RxNorm normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab 6mg loading dose followed by 3mg (6mgLD+3mgQ4wk)
Trial: 22169830
Drug: Lifestyle course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle course in combination with physical activity (intervention group)
Trial: 20798560
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with bevacizumab (leucovorin, 5-fluorouracil plus irinotecan)
Trial: 20798560
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (leucovorin, 5-fluorouracil plus irinotecan)
Trial: 20798560
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with bevacizumab
Trial: 16213302
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg, three times a day, 12 weeks)
Trial: 16213302
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir (5 mg/kg, 2 weeks)
Trial: 16213302
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intravenous ganciclovir
Trial: 10685331
Drug: GnRHa plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa plus oral estriol 4 mg/day for 4 months (add-back group; n = 6)
Trial: 10685331
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot alone at a dose of 3.75 mg s.c. every month for 6 months (non add-back group; n = 6)
Trial: 10685331
Drug: GnRHa plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa plus oral estriol add-back therapy
Trial: 8763462
Drug: Lamisil (terbinafine)
RxNorm normalized name: Lamisil
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamisil (terbinafine) 250 mg/day
Trial: 1811337
Drug: Fish diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish diet (200 g/d of lean Australian fish flesh)
Trial: 1811337
Drug: Fish +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish + Oil diet (200 g/d of lean Australian fish flesh + 5 g/d fish oil)
Trial: 6130658
Drug: Pindolol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (0.4 mg i.v.)
Trial: 6130658
Drug: Metoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (5 mg i.v.)
Trial: 6740566
Drug: Heparin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin treatment (subcutaneous or intravenous)
Trial: 22679142
Drug: Coumarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumarin treatment
Trial: 30587933
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of Bbr with Fbt and Svt
Trial: 29451825
Drug: Social Cognition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Cognition and Object Relations Scale-Global Rating Method (SCORS-G)
Trial: 27251185
Drug: Cranberry beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry beverage (240 mL/day)
Trial: 24864125
Drug: TIV followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIV followed by AS03-adjuvanted A(H1N1)pdm09 vaccine
Trial: 24864125
Drug: TIV followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIV followed by nonadjuvanted A(H1N1)pdm09 vaccine
Trial: 24864125
Drug: Saline followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline followed by AS03-adjuvanted A(H1N1)pdm09 vaccine
Trial: 24864125
Drug: Saline followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline followed by nonadjuvanted A(H1N1)pdm09 vaccine
Trial: 20190704
Drug: Method C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method C (Integran, a sheet-type absorbable topical collagen hemostat)
Trial: 20190704
Drug: Method G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method G (combined approach with TachoComb or PGA sheet fixed with fibrin glue)
Trial: 17659194
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/day with CYP3A4-MET statins
Trial: 17659194
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/day with non-CYP3A4-MET statins
Trial: 17659194
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/day with atorvastatin
Trial: 20097702
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with atorvastatin
Trial: 17659194
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/day with pravastatin
Trial: 12657846
Drug: Parecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (40 mg intravenously every 12 h)
Trial: 11140216
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicines
Trial: 2064956
Drug: Daunorubicin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin (two doses on the first 2 days of induction)
Trial: 2064956
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without daunorubicin
Trial: 2064956
Drug: Treatment continued
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment continued for 3 years
Trial: 2064956
Drug: Treatment stopped
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment stopped after 2 years
Trial: 2064956
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (including all agents)
Trial: 6367371
Drug: Atenolol 50-100
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50-100 mg once daily
Trial: 6367371
Drug: Captopril 25-50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25-50 mg 3 times daily
Trial: 6367371
Drug: Captopril combined
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril combined with hydrochlorothiazide (25-50 mg)
Trial: 6367371
Drug: Atenolol combined
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol combined with hydrochlorothiazide (25-50 mg)
Trial: 24395497
Drug: Transradial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transradial intervention (TRI) and bivalirudin infusion
Trial: 24395497
Drug: Transfemoral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transfemoral intervention (TFI) and unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI)